Technology histories tend to be written about devices. But the pace at which a technology reaches patients is set by people — by what clinicians will implant, what regulators will approve, and what ethicists will permit.
China's brain–computer interface programme is interesting precisely because that conversation is happening in public, and in disagreement.
Key takeaways
- Clinicians are setting the standard for evidence. Surgeons involved in the BeiNao-1 trials have emphasised that no serious complications have appeared across the cohort and that signal quality has remained stable — while stressing that a BCI is not an ordinary implantable device, because "implantation is only the beginning."
- A new profession is being invented. Because patients and devices must adapt to each other, the field is exploring the creation of a "brain–computer interface clinical adaptation physician" — a role that does not exist anywhere else in medicine.
- Researchers disagree on the right technical path. Some argue China should advance invasive and non-invasive approaches in parallel, matching its own strengths and application needs. Others note that social acceptance of invasive technology is extremely low because it requires craniotomy, which pushes industry toward non-invasive alternatives.
- Legal scholars are reframing the data question. One prominent argument holds that neural data rights are fundamentally different from ordinary digital data because they carry both personality-rights and data-rights attributes simultaneously.
The clinicians
The surgical leadership has been notably careful in public. Cao Yong, executive deputy director of the Neurosurgery Center at Beijing Tiantan Hospital, has described reviewing the earlier BeiNao-1 cases and finding no serious complications, with all patients maintaining stable and clear electrical signals.
He has also made a point that cuts against hype: BCI differs from general implantable medical devices because the surgery is only the start. Patients and devices must cooperate and adapt to one another. That is why the field is discussing a dedicated clinical-adaptation specialty — to build the professional workforce that large-scale deployment will require.
This kind of statement matters. It is the voice of a profession setting expectations before a technology disappoints the public.
The engineers and researchers
Ming Dong, vice president of Tianjin University and head of its Haihe Laboratory of Brain–Computer Interaction and Human–Machine Integration, leads the team behind the "Shengong" series, which has produced results in clinical BCI-assisted rehabilitation, brain-function assessment and modulation, and even brain–computer interaction in space.
His stated position is that China should build on its own strengths and application needs while advancing both technical routes in parallel: invasive approaches for targeted disease treatment and high-precision research, and non-invasive approaches for safety, convenience, reusability and scale.
Ma Yide, dean of the School of Intellectual Property at the University of the Chinese Academy of Sciences, has argued that restorative BCIs hold the greatest near-term commercial potential — in medical rehabilitation, assistance for people with disabilities, and treatment of neurological disorders — and that over the medium to long term the field may converge with embodied intelligence, intelligent robotics and digital healthcare.
The sceptics
Not everyone is convinced that the harder path is the right one.
Li Zhen, deputy dean of the School of Marxism at Sun Yat-sen University, has observed that while invasive technology offers transformative potential, social acceptance remains extremely low because it requires opening the skull — pushing the industry toward non-invasive alternatives. But she notes those alternatives face inherent limits in signal precision and information throughput.
She has also warned that public understanding of BCI fundamentals, data rights and usage boundaries remains limited, producing both irrational fear and inflated expectations — a combination that is dangerous for any emerging technology.
The lawyers and ethicists
The most original thinking may be happening in law faculties.
Yang Dong, dean of the Law School at Renmin University of China, has argued that BCIs differ fundamentally from digital-economy technologies because the rights involved are simultaneously personality rights and data rights. He has proposed piloting regulatory sandboxes to build practical experience ahead of legislation, with dedicated rules for neural data privacy, data property rights and benefit allocation.
Li Lun, head of the Centre for Artificial Intelligence Ethics at Hunan Normal University, has stressed that invasive BCI remains at the clinical trial stage and must be supported by sufficient evidence from animal experiments.
This is the substance behind the standards documents: not bureaucracy, but an attempt to answer questions — Who owns a thought? Who is liable when a decoder errs? How is consent obtained from someone who cannot speak? — that have no precedent in any legal system.
Why this matters more than the prototypes
A country can build an implant. Building the clinical, legal and ethical apparatus that lets it be used safely by tens of thousands of people is much harder, and it is where China's BCI programme is currently spending most of its institutional energy.
The engineers will keep improving the devices. Whether those devices become medicine will be decided by the people arguing about the line.
Attributions based on expert interviews and commentary published in Chinese academic and state media in 2026.